Medical/Pharmaceuticals

JW Therapeutics Announces IND Approval for the Clinical Trial of JWCAR129

SHANGHAI, Sept. 27, 2021 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, today announced that it has received the Investigational New Drug (IND) clearance from the National Medi...

2021-09-27 20:00 4843

Senhwa Announces Acceptance of Early Positive COVID-19 Phase II Study Abstract for Presentation at the ISIRV-WHO Conference

* Early Positive Phase 2 efficacy and safety data are both statistically significant and clinically meaningful. * No SAE related to Silmitasertib was reported. * Silmitasertib is a host-directed antiviral and an anti-inflammatory investigational therapy expected to be effective against eme...

2021-09-27 19:20 3459

Seegene Unveils Fully Automated Molecular Testing System at the 2021 AACC

* Seegene unveils its first fully automated MDx system, STARlet-AIOS: All-in-One System at the 2021 AACC held in theAtlanta, GA, United States * AIOS is the MDx system that integrates Seegene's liquid handler and real-time PCR instruments. * Seegene MDx system will efficiently access a wide ...

2021-09-27 19:02 3399

GenScript ProBio Congratulates EyeGene for Clinical Trial Approval for mRNA COVID-19 Vaccine in South Korea

NANJING, China, Sept. 27, 2021 /PRNewswire/ -- EyeGene's mRNA vaccine against COVID-19, namely "EG-COVID", has recently been approved for clinical trials by South Korea's Ministry of Food and Drug Safety (MFDS). GenScript ProBio hereby extended its warm congratulations to the partner. EG-COVID ...

2021-09-27 18:35 3251

Lipidor announces approval to start Phase III clinical study of drug candidate AKP02 for treatment of psoriasis

STOCKHOLM, Sept. 27, 2021 /PRNewswire/ -- Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announced today that the company's Phase III clinical study of its drug candidate AKP02 for the treatment of psoriasis has been approved by the Indian Medical Products Agency and is ready to start...

2021-09-27 17:37 2070

Mindray Launches New MC-80 Automated Digital Cell Morphology Analyzer, Taking Morphology Analysis to the Next Level

SHENZHEN, China, Sept. 27, 2021 /PRNewswire/ -- Mindray (SZSE: 300760), a global leading medical solution provider, has launched the new MC-80 Automated Digital Cell Morphology Analyzer, a revolutionary cell morphology system that provides more clarity, more intelligence and more productivity for...

2021-09-27 16:20 5486

Clever Culture Systems Appoints Thermo Fisher Scientific as Exclusive US APAS® Distributor

ADELAIDE, Australia, Sept. 27, 2021 /PRNewswire/ -- Australian medical technology company LBT Innovations Limited (ASX: LBT) (LBT or the Company), a leader in medical technology automation using artificial intelligence, is pleased to announce the signing of an exclusive Distribution Agreement for...

2021-09-27 16:00 2158

Transcenta Received IND Clearance from NMPA of its Anti-sclerostin Monoclonal Antibody TST002

SUZHOU, China, Sept. 26, 2021 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it received IND clearance on...

2021-09-27 08:30 1503

Innovent and AnHeart Announce Interim Data from Phase 2 Trial of Taletrectinib in ROS1-Positive NSCLC at the CSCO 2021 Annual Meeting

SAN FRANCISCO and SUZHOU, China, Sept. 27, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major disea...

2021-09-27 08:00 4622

Kintor Pharma Announces Brazil's ANVISA Approves Phase III Clinical Trial of Proxalutamide for the Treatment of Hospitalized COVID-19 Patients

SUZHOU, China, Sept. 26, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that onSeptember 22 the Brazilian Health Regulatory Agency (ANVISA) ...

2021-09-26 23:09 6559

GenScript ProBio and AskGene Enter into a Non-exclusive License of A sdAb Targeting Immune Checkpoint Target

NANJING, China, Sept. 26, 2021 /PRNewswire/ -- On September 26, 2021, GenScript ProBio and AskGene signed a license agreement forGenScript ProBio's single-domain antibody (sdAb) targeting an immune checkpoint target.GenScript ProBio grants a non-exclusive global license to AskGene to use GenScrip...

2021-09-26 22:28 2632

JW Therapeutics Announces Updated 1-year Follow-up Result of Relmacabtagene Autoleucel Injection At the 24th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO)

SHANGHAI, Sept. 26, 2021 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, today announced updated 1-year follow-up result of relmacabtagene autoleucel injection (relma-cel) for t...

2021-09-26 20:00 5312

Boan Biotech to Present the Pre-clinical Data of Its Proprietary CD3+ T-cell Engager Platform and CEA/CD3 Bispecific Antibody at World Bispecific Summit

Sept. 25, 2021, BOSTON /PRNewswire/ -- Boan Biotech, a subsidiary of Luye Pharma Group, will orally present the pre-clinical data of its proprietary CD3+ T-cell engager platform and CEA/CD3 bispecific antibody at World Bispecific Summit 2021. The annual World Bispecific Summit aiming to promote ...

2021-09-26 10:12 2560

Qiming's Portfolio Company Broncus Lists on Main Board of HKEx

SHANGHAI, Sept. 24, 2021 /PRNewswire/ -- Qiming Venture Partners' portfolio company Broncus (SEHK:2216),  a pioneer inChina's interventional pulmonology navigation device market, today listed on the main board of Hong Kong Stock Exchange. The issue price isHK$ 18.7/share, representing a market ca...

2021-09-24 14:10 13633

New Drug Application for Cadonilimab (PD-1/CTLA-4 Bi-Specific Antibody) for the Treatment of Relapsed or Metastatic Cervical Cancer Accepted by NMPA

HONG KONG, Sept. 24, 2021 /PRNewswire/ -- Akeso, Inc. (the Company, 9926.HK) announces that the National Medical Products Administration (the NMPA) ofChina has officially accepted the new drug application for the world's first-in-class Cadonilimab (PD-1/CTLA-4 bi-specific antibody, research and d...

2021-09-24 14:09 2510

Everest Medicines Announces Approval of Investigational New Drug Application by China NMPA for SPR206

SHANGHAI, Sept. 24, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inAsia, an...

2021-09-24 13:56 4792

Broncus Lists on Main Board of HKEx

HONG KONG, Sept. 24, 2021 /PRNewswire/ -- On September 24, Broncus (02216.HK), a pioneer in the field of interventional pulmonology inChina, was successfully listed on the main board of the Hong Kong Stock Exchange. Broncus, founded in 2012, is a medical device company focused on the development...

2021-09-24 11:52 6817

New Drug Application for Cadonilimab (PD-1/CTLA-4 Bi-Specific Antibody) for the Treatment of Relapsed or Metastatic Cervical Cancer Accepted by NMPA

HONG KONG, Sept. 23, 2021 /PRNewswire/ -- Akeso, Inc. (the Company, 9926.HK) announces that the National Medical Products Administration (the NMPA) ofChina has officially accepted the new drug application for the world's first-in-class Cadonilimab (PD-1/CTLA-4 bi-specific antibody, research and d...

2021-09-24 09:18 4200

Johnson & Johnson Innovation Announces Awardees of the Digital Technologies of Tomorrow QuickFire Challenge

Awardees HelpWear and Us2.ai recognized for their novel ideas to harness the Internet of Things (IoT) and Artificial Intelligence (AI) with the aim to transform Atrial fibrillation (AFIB) patient care. SHANGHAI, Sept. 24, 2021 /PRNewswire/ -- Johnson & Johnson Innovation LLC together with Johnso...

2021-09-24 09:02 4344

Results from Novavax NanoFlu Influenza Vaccine Phase 3 Clinical Trial Published in The Lancet Infectious Diseases

- Pivotal Phase 3 trial achieved all primary endpoints, demonstrating non-inferiority to a leading U.S.-licensed quadrivalent influenza vaccine - NanoFlu™ vaccine candidate induced significantly enhanced cell-mediated immune responses - NanoFlu was well-tolerated with a comparable safety profile...

2021-09-24 08:47 6303
1 ... 631632633634635636637 ... 645